Proteus® proton therapy solutions fully meet the criteria published by Unicancer's experts.
Louvain-la-Neuve, Belgium, 28 October 2020 - IBA (Ion Beam Applications SA, EURONEXT), the world’s leading provider of proton therapy solutions for the treatment of cancer, announced today that Unicancer, the only hospital network in France entirely dedicated to the fight against cancer, has selected IBA Proteus® proton therapy solutions for its network. IBA is one of only two licensees selected for the next three years for both the single-room and multi-room systems.
The French hospital federation Unicancer brings together 18 cancer centers, known as French Comprehensive Cancer Centers (FCCC), which are private non-profit healthcare institutions spread over 20 hospital sites in France. The FCCCs treat more than 530,000 patients per year.
Unicancer has published their ranking of authorized suppliers for the procurement of the supply, delivery, installation and maintenance of proton therapy equipment for its members. The federation particularly recognized the technical and clinical qualities of IBA's two proton therapy solutions: the single-room Proteus®ONE and multi-room Proteus®PLUS. The offer submitted by IBA also included options for financing as well as for the construction of the buildings.
IBA will retain this position as contract holder until 2023. During this period, FCCCs will be able to place purchase orders with IBA. Four centers have already expressed interest in market consultation.
IBA is already the provider of the three existing proton therapy centers in France with its solutions at Institut Curie in Paris, Centre Antoine Lacassagne in Nice and Centre François Baclesse in Caen. All are members of the Unicancer network, which facilitates possible clinical and technical collaborations with future centers.
Olivier Legrain, Chief Executive Officer at IBA, commented: “We are pleased that once again IBA's proton therapy solutions are recognized as being at the forefront of the proton therapy market after a very careful evaluation process by Unicancer experts. We are delighted with this partnership with UNICANCER, a world-renowned network of excellence in the field of cancer care, research and education.”
***Ends***
About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.
IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com
* Proteus®PLUS and Proteus®ONE are the brand name of Proteus®235
For further information, please contact:
IBA
Aymeric Harmant
Global Marketing Director
+32 10 203 796
global.marketing@iba-group.com